NEK2 inactivates the Hippo pathway to advance the proliferation of cervical cancer cells by cooperating with STRIPAK complexes

Cancer Lett. 2022 Nov 28:549:215917. doi: 10.1016/j.canlet.2022.215917. Epub 2022 Sep 14.

Abstract

The never in mitosis gene A (NIMA)-related kinase 2 (NEK2) protein has been reported to be an oncoprotein that plays different oncogenic roles in multiple cancers. Here, we confirmed that NEK2 highly expressed in cervical cancer cells rather than in normal epithelial basal layer cells in cervical tissues and correlated with worse outcomes. We also demonstrated that NEK2 promoted the in vivo growth of subcutaneous xenograft tumors stemming from cervical cancer cells and the in vitro cell proliferation by decreasing Ser127-phosphorylation of the YAP protein retained in the cytoplasm while increasing the levels of active nucleus-associated YAP protein, which was followed by increases in the targeted proteins CTGF, CYR61 and GLI2. Furthermore, the Hippo signaling pathway was inactivated in manipulated NEK2-overexpressing cervical cancer cells by regulating the levels of MST1/2 dephosphorylation. Additionally, mass spectrometric sequencing and bilateral coimmunoprecipitation were employed suggested that NEK2 acted at an early upstream step to promote dephosphorylation of MST2 and inactivate the Hippo signaling cascade by cooperating with STRIPAK complexes. We conjecture that NEK2 may be a future target for cervical cancer therapy.

Keywords: Cervical cancer; MST2; NEK2; STRN; YAP.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Cell Proliferation
  • Female
  • Hippo Signaling Pathway
  • Humans
  • NIMA-Related Kinases / genetics
  • NIMA-Related Kinases / metabolism
  • Phosphorylation
  • Protein Serine-Threonine Kinases*
  • Uterine Cervical Neoplasms* / genetics

Substances

  • NEK2 protein, human
  • NIMA-Related Kinases
  • Protein Serine-Threonine Kinases